...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study
【24h】

Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study

机译：流行病学特征，高级非小细胞肺癌患者的EGFR状态和管理模式：希腊理性观察登记研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Real-world evidence regarding the prevalence of epidermal growth factor receptor (EGFR) mutation-positive status (M+) and the clinicopathological characteristics associated with the presence of EGFR mutations in advanced non-small cell lung cancer (NSCLC) is scarce, especially among Caucasian populations. The present study aimed to bridge this gap, as well as to record treatment patterns and outcomes in routine-care settings. Patients and Methods: REASON (NCT01153399) was a prospective study of patients with stage IIIB/IV NSCLC and known EGFR mutation status. Clinicopathological, treatment characteristics and clinical outcomes were recorded and correlated with EGFR mutation testing results. Results: Of 575 enrolled patients, EGFR mutations were detected in 15.7% of them. Male gender (p=0.008) and smoking (p0.001), but not adenocarcinoma, were associated with EGFR M+ status. In the EGFR M+ subpopulation (n=88), absence of bone and/or brain metastasis and presence of exon 19 EGFR M+ status at diagnosis were independently associated with longer progression free survival (PFS) (p=0.011 and p=0.040, respectively). Conclusion: In our population, males and smokers had decreased odds of harboring an EGFR mutation, while adenocarcinoma histology was not a significant predictor of EGFR M+ status. EGFR M+ patients with bone and/or brain metastases at diagnosis or mutations other than exon 19 deletions were at increased risk for earlier disease progression.
机译：背景/目的：关于表皮生长因子受体（EGFR）突变阳性地位（M +）的普遍性的真实迹象以及与晚期非小细胞肺癌（NSCLC）中的EGFR突变相关的临床病理特征是稀缺的，特别是在白人人群中。本研究旨在弥合这种差距，以及记录常规护理环境中的治疗模式和结果。患者和方法：原因（NCT01153399）是对IIIB / IV NSCLC和已知EGFR突变状态患者的前瞻性研究。记录临床病理，治疗特征和临床结果与EGFR突变检测结果相关。结果：575名注册患者，在其中的15.7％中检测到EGFR突变。男性性别（P = 0.008）和吸烟（P <0.001），但不是腺癌，与EGFR M +状态相关。在EGFR M +亚泊素（n = 88）中，诊断中没有骨和/或脑转移和外显子的存在和外显子的eGFR M +状态与更长的进展自由存活（PFS）分别独立相关（P = 0.011和P = 0.040 ）。结论：在我们的人口中，男性和吸烟者患有EGFR突变的几率降低，而腺癌组织学不是EGFR M +状态的显着预测因子。 EGFR M +患者骨骼和/或脑转移患者在外显子19缺失以外的诊断或突变中均为早期疾病进展的风险增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号